Skip to main content
. 2022 Dec 26;13(4):1467–1487. doi: 10.1016/j.apsb.2022.12.016

Figure 3.

Figure 3

Combination strategies regulate T cell-mediated response. (A) The SIRPα–4-1BBL fusion protein or CD47/PD-1 bispecific antibody could not only block CD47 to enhance phagocytosis but also activate T cell-mediated immune response. Besides, the combination effect of co-targeting CD47 and PD-L1 relies on T cell activation. (B) Unselective depletion of Tregs in periphery by anti-CTLA-4 antibody contributes to immune-related adverse effects. The anti-CTLA-4–SIRPα heterodimer is developed to reduce the binding of agents targeting CD47 to RBCs and precisely deplete tumor Tregs. (C) Selection of CD47 as the TAA for CAR-T therapy increases T cell recognition to cancer cells. CD47 Ab, anti-CD47 antibody; PD-L1 Ab, PD-L1 antibody; CD47/PD-L1, bispecific antibody targeting CD47 and PD-L1; CD47/PD-1, bispecific antibody targeting CD47 and PD-1; CTLA-4-SIRPα: anti-CTLA-4–SIRPα heterodimer.